Clinical trials: Influenza Type B
Influenza Type A, Influenza Type B
Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants
Influenza causes substantial morbidity and mortality worldwide despite available antivirals and vaccines. SAB Biotherapeutics, Inc.
- Conditions
- Influenza Type A, Influenza Type B, Influenza
- Trial name
- NCT04471038
- Testing
- SAB-176, Normal Saline
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- SAb Biotherapeutics, Inc.
Influenza, Human
Prevalence, Strain Circulation and Disease Burden Study of Seasonal Influenza A and B in Panama, Selected Countries of Central America and the Caribbean From the Year 2010 to 2015
The purpose of this study is to assess the prevalence, strain circulation and disease burden of seasonal Influenza A and B in Panama, selected countries of Central America and the Caribbean from the Year 2010 to 2015.
- Trial name
- NCT02885246
- Testing
- Data collection
- Where
- Panama
- Volunteers
- 1,839 people
- Sponsor
- GlaxoSmithKline
Immunization
Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants
The purpose of this study is to evaluate the safety and efficacy of an intramuscular injection of BK1310 in healthy infants.
- Trial name
- NCT03188692
- Testing
- DPT-IPV-Hib (Combined Vaccine)
- Where
- 3 sites in Japan
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Influenza
Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®
To describe the safety findings from Days 0 to 44 following injection of the 2003-2004 pediatric formulation of the inactivated, split-virion influenza vaccine Fluzone®, given in the two-dose schedule in accordance with the…
- Trial name
- NCT00836953
- Testing
- Influenza virus vaccine (Pediatric formulation)
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19 Respiratory Infection, Influenza A
Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit
To compare the results obtained by analysis of a self-collected anterior nasal (AN) swab as part of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit to a healthcare provider (HCP)-collected AN swab in patients with symptoms…
- Conditions
- COVID-19 Respiratory Infection, Influenza A, Influenza Type B, RSV Infection
- Trial name
- NCT06008457
- Testing
- Labcorp COVID-19+Flu+RSV Test Home Collection Kit
- Where
- United States
- Volunteers
- 1,600 people
- Sponsor
- Sequenom, Inc.
COVID-19, Influenza A
Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 Assessment
A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 \& FLU A/B Test, and LumiraDx SARS-CoV-2 \& RSV Test at Point of Care Testing Sites.
- Conditions
- COVID-19, Influenza A, Influenza Type B, RSV Infection
- Trial name
- INSPIRE-2 (NCT05268939)
- Testing
- LumiraDx SARS-CoV-2 & Flu A/B test, LumiraDx SARS-CoV-2 & RSV test
- Where
- 8 sites in United States
- Volunteers
- 589 people
- Sponsor
- LumiraDx UK Limited
SARS-CoV-2, Influenza A
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test
This is a prospective multicenter study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 \& Flu A/B tests at point of care sites.
- Conditions
- SARS-CoV-2, Influenza A, Influenza B, Asymptomatic COVID-19
- Trial name
- ITAP1489 (NCT05787444)
- Testing
- LumiraDx SARS-CoV-2 & Flu A/B
- Where
- United States
- Volunteers
- 1,081 people
- Sponsor
- LumiraDx UK Limited
Influenza
Collection and Extraction of Respiratory Specimens
The study will be conducted with nasopharyngeal swab specimens collected prospectively from individuals suspected of having an acute respiratory tract infection caused by an Influenza virus.
- Trial name
- NCT01083511
- Where
- 3 sites in United States
- Volunteers
- 600 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Influenza
Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older
The purpose of this study is to determine the efficacy, safety and tolerability of the liquid formulation of CAIV-T against culture confirmed influenza illness in adults aged 60 years and older.
- Trial name
- NCT00217230
- Testing
- CAIV-T
- Where
- South Africa
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC